Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s National Medical Products Administration (NMPA) has approved the Phase I clinical study of AST1001 injection, the company’s independently developed antibody‑drug conjugate (ADC), for the treatment of adult patients with locally advanced or metastatic solid tumors who have failed prior standard therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Phase I clinical trial (IND) |
| Product | AST1001 injection (ADC) |
| Indication | Locally advanced or metastatic solid tumors in adults refractory to prior standard therapy |
| Approval Date | 7 Nov 2026 |
| Parallel Filing | US FDA approved the same Phase I study for the identical indication in October 2026 |
| Next Steps | Trial initiation, dose escalation and safety assessment; timelines not yet disclosed |
Drug Profile & Mechanism of Action
- Molecule: Antibody‑drug conjugate (ADC) with proprietary intellectual property rights, independently developed by Allist Pharmaceuticals.
- Antibody Component: A bispecific antibody simultaneously targeting epidermal growth factor receptor (EGFR) and mesenchymal‑epithelial transition factor (c‑MET) — two receptor tyrosine kinases frequently co‑expressed or co‑activated in refractory solid tumors and associated with resistance to single‑agent targeted therapy.
- Payload: A topoisomerase I (Topo‑I) inhibitor payload‑linker developed in‑house, the same drug class that underpins several clinically validated ADCs in oncology.
- Design Rationale: Dual‑antigen targeting is intended to broaden tumor coverage, enhance receptor‑mediated internalization, and potentially overcome escape mechanisms seen with single‑target EGFR or c‑MET inhibitors.
Development Status – Phase I
- Trial Phase: First‑in‑human Phase I; primary objectives typically include safety, tolerability, pharmacokinetics and preliminary antitumor activity.
- Study Population: Adults with locally advanced or metastatic solid tumors who have exhausted standard treatment options — a population with high unmet medical need and limited therapeutic alternatives.
- Trial Design Details: Sites, sample size, dosing schedule and endpoints – not disclosed.
- Dual‑Jurisdiction Strategy: With NMPA (November 2026) and FDA (October 2026) clearances secured within weeks of each other, AST1001 is positioned for parallel clinical development in both China and the United States.
Market Impact & Outlook
- ADC Landscape: Antibody‑drug conjugates remain one of the hottest modalities in global oncology dealmaking; bispecific ADCs represent the emerging next wave, aiming to improve tumor selectivity over first‑generation single‑target constructs.
- Target Combination: EGFR and c‑MET co‑targeting addresses documented resistance pathways in multiple solid tumor types, potentially differentiating AST1001 from approved single‑antigen ADCs.
- Pipeline Signal: The rapid back‑to‑back FDA and NMPA approvals underscore Allist’s accelerating R&D execution and its ambition to advance proprietary oncology assets into global clinical development.
- Commercial Outlook: Too early to assess; no efficacy, safety or partnering data have been disclosed. Milestone value will depend on Phase I readouts.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical trial outcomes, and development plans for AST1001. Actual results may differ materially due to risks including clinical safety findings, enrollment progress, subsequent regulatory requirements, and competitive dynamics in the ADC field. No efficacy or commercial projections have been disclosed by the company.-Fineline Info & Tech
